AnaptysBio Inc (ANAB)

Currency in USD
20.37
-2.17(-9.63%)
Closed·
After Hours
20.33-0.04(-0.20%)
·
ANAB Scorecard
Full Analysis
Quickly burning through cash
ANAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.2623.67
52 wk Range
12.2141.31
Key Statistics
Prev. Close
22.54
Open
23.56
Day's Range
20.26-23.67
52 wk Range
12.21-41.31
Volume
527.45K
Average Volume (3m)
574.04K
1-Year Change
-29.77%
Book Value / Share
1.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.00
Upside
+140.55%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

AnaptysBio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

AnaptysBio Inc Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Compare ANAB to Peers and Sector

Metrics to compare
ANAB
Peers
Sector
Relationship
P/E Ratio
−4.7x−1.1x−0.5x
PEG Ratio
−0.20−0.060.00
Price/Book
19.5x2.2x2.6x
Price / LTM Sales
5.9x9.2x3.3x
Upside (Analyst Target)
118.2%307.6%43.5%
Fair Value Upside
Unlock18.5%6.9%Unlock

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 49.00
(+140.55% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-1.34 / -1.52
Revenue / Forecast
22.26M / 11.51M
EPS Revisions
Last 90 days

ANAB Income Statement

People Also Watch

3.52
ALT
-2.22%
19.210
LQDA
-5.42%
13.25
STOK
+0.61%
15.16
OSCR
+5.68%

FAQ

What Stock Exchange Does AnaptysBio Trade On?

AnaptysBio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for AnaptysBio?

The stock symbol for AnaptysBio is "ANAB."

What Is the AnaptysBio Market Cap?

As of today, AnaptysBio market cap is 597.01M.

What Is AnaptysBio's Earnings Per Share (TTM)?

The AnaptysBio EPS (TTM) is -4.79.

When Is the Next AnaptysBio Earnings Date?

AnaptysBio will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is ANAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has AnaptysBio Stock Split?

AnaptysBio has split 0 times.

How Many Employees Does AnaptysBio Have?

AnaptysBio has 136 employees.

What is the current trading status of AnaptysBio (ANAB)?

As of 07 Aug 2025, AnaptysBio (ANAB) is trading at a price of 20.37, with a previous close of 22.54. The stock has fluctuated within a day range of 20.26 to 23.67, while its 52-week range spans from 12.21 to 41.31.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.